HCW Biologics Q2 FY26 net loss widens to $5.2 million; revenue rises to $135,568
HCWB•Q2 financial results
HCW Biologics posted Q2 net loss of USD 5.2 million, widening from USD 1.9 million a year earlier.
Revenue climbed to USD 135,568 from USD 6,550; R&D held at USD 1.2 million while G&A fell 11% to USD 1.9 million.
HCW9302 Phase 1 alopecia areata study
HCW9302 Phase 1 alopecia areata study showed early SALT score improvements in cohort two; no dose-limiting toxicities were reported.
Management said HCW9302’s CD25 targeting supports regulatory T-cell expansion; full Phase 1 readout remains slated for Q4 2026.
Six-month revenue and licensing update
Six-month revenue rose to USD 6.7 million from USD 11,615, driven by closing the Trimmune License for HCW11-006 in vivo rights.
